請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77701
標題: | 評估臺灣紫芝胞外多醣體抑制肺腫瘤之效果與機制 Evaluation of Inhibitory Effects of Exopolysaccharide from Ganoderma formosanum on Lung Tumor and Its Mechanism |
作者: | Chi-Chin Lum 林芷晴 |
指導教授: | 鄭光成(Kuan-Chen Cheng) |
關鍵字: | 臺灣紫芝,液態深層醱酵,β-1,3-葡聚醣,Lewis Lung Carcinoma, Ganoderma formosanum,submerged fermentation,β-1,3-glucan,Lewis Lung Carcinoma, |
出版年 : | 2017 |
學位: | 碩士 |
摘要: | 中藥的現代化是指以繼承和發揚中醫藥優勢和特色作為基礎,充分利用現代科學技術對中藥進行研究,以適應社會發展需求。而靈芝為上藥中的王者,可謂是中藥最具代表性的上上之品。近來靈芝多醣體相關的研究發現,β-1,3-葡聚醣為多醣體之活性成分,具有抗腫瘤與免疫調節之功能。目前對於靈芝功效之研究主要以赤芝 (Ganoderma lucidum) 為主,臺灣紫芝 (Ganoderma formosanum)為臺灣特有種靈芝,先前研究發現其β-1,3-葡聚醣含量特高。本研究利用皮下注射LLC1 (Lewis Lung Carcinoma) 肺癌細胞的C57BL/6小鼠作為荷瘤動物模式,評估由液態深層醱酵培養獲得的臺灣紫芝胞外多醣體 (GF-EPS) 對LLC你 1肺癌細胞所產生的抗腫瘤與免疫調節作用,並以化學分析方法進一步釐清此類多醣體的性質。GF-EPS中β-1,3-glucan的量達48.91 ± 0.71%, D-glucose (51.89 ± 1.75%) 為最主要的單糖。In vitro細胞實驗的結果顯示GF-EPS對LLC1沒有直接的毒殺性。然而,LLC1荷瘤小鼠的抗腫瘤實驗顯示,管餵GF-EPS可抑制LLC1之生長。有預先餵食GF-EPS (80 mg/kg) 之Preventive和皮下注射LLC1細胞後才開始餵食GF-EPS之Therapeutic組別的小鼠,LLC1腫瘤抑制率分別達40.32%和32.77%。經過GF-EPS餵食之小鼠脾臟淋巴細胞,其自然殺手細胞有明顯增加,推測GF-EPS可刺激自然殺手細胞的增值,以利毒殺癌細胞。此外,GF-EPS有助於提高利於抗腫瘤之細胞激素及Th1輔助細胞的基因表現量,以及可能抑制Tregs的產生。綜合以上結果,初步證實推測含有高量β-1,3-葡聚醣之GF-EPS,能透過刺激宿主的免疫系統,達到抗LLC1腫瘤的作用。 Development of science and technology provide a favorable condition for the modernization of traditional Chinese medicine. Ganoderma is one of the most valued Chinese traditional medicines. Antitumor and immunomodulatory characteristics of β-1,3-glucan, a well-recognized bioactive polysaccharide of Ganoderma, were reported. However, most studies of Ganoderma were focused on g. lucidum. Ganoderma formosanum is an endemic species of Ganoderma in Taiwan. In previous studies, β-1,3-glucan in G. formosanum EPS was significantly higher than that in other species. In the present study, we evaluated inhibitory effects of GF-EPS, exopolysaccharide from submerged fermentation of G. formosanum, in Lewis Lung Carcinoma (LLC1) tumor-bearing mice. Result of in vitro assay showed that GF-EPS did not cause direct cytotoxicity against LLC1 while continuous oral administration of GF-EPS (80 mg/kg) effectively suppressed the growth of LLC1 tumor cells in tumor-bearing mice in both preventive and therapeutic model. The increased percentage of natural killer cells in treatment groups indicated that GF-EPS may stimulate proliferation of these cells in tumor-bearing mice. Furthermore, gene expression of cytokines which function in inhibiting tumor development was elevated in treatment groups. Additionally, the results also suggested that GF-EPS may play a potential role as both Th1 stimulator and Tregs suppressor in tumor environment. Taken together, these findings provided evidences that GF-EPS has immunomodulation effects on mouse immune cells and therefore exhibit potent antitumor properties. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77701 |
DOI: | 10.6342/NTU201703349 |
全文授權: | 未授權 |
顯示於系所單位: | 食品科技研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-R04641039-1.pdf 目前未授權公開取用 | 4.87 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。